## Protocol Section
### Identification Module
**NCT ID:** NCT06112379

**Brief Title:** A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

**Official Title:** A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)

#### Organization Study ID Info
**ID:** D926QC00001
#### Organization
**Class:** INDUSTRY
**Full Name:** AstraZeneca
### Status Module
#### Completion Date
**Date:** 2030-08-28

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-05-14

**Type:** ACTUAL

**Last Update Submit Date:** 2024-05-13

**Overall Status:** RECRUITING

#### Primary Completion Date
**Date:** 2028-03-29

**Type:** ESTIMATED

#### Start Date
**Date:** 2023-11-14

**Type:** ACTUAL

**Status Verified Date:** 2024-05

#### Study First Post Date
**Date:** 2023-11-01
**Type:** ACTUAL
**Study First Submit Date:** 2023-10-12
**Study First Submit QC Date:** 2023-10-31
### Sponsor Collaborators Module

#### Collaborators

**Class:** INDUSTRY

**Name:** Daiichi Sankyo

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** AstraZeneca

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

**Oversight Has DMC:** True

### Description Module

**Brief Summary:** This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

**Detailed Description:** The primary objectives of the study are to demonstrate superiority of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy relative to neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor low/HER2-negative breast cancer, by central assessment of pCR and/or to demonstrate superiority of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy relative to neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer, by investigator assessment of EFS

### Conditions Module

**Conditions:**

- Breast Cancer

**Keywords:**

- Breast Cancer;

- Dato-DXd; DS1062a;

- TROP2;

- TNBC;

- HR low:

- Datopotamab deruxtecan;

- Antibody Drug Conjugate;

- ADC;

- neoadjuvant therapy;

- adjuvant therapy;

- durvalumab;

- PD-L1;

- immune-checkpoint inhibitor (ICI);

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** PARALLEL

**Intervention Model Description:** Participants will be randomised in a 1:1 ratio to one of two intervention groups.

##### Masking Info

**Masking:** NONE

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 1728

**Type:** ESTIMATED

**Phases:**

- PHASE3

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Participants receive durvalumab every 3 weeks (Q3W) + Dato-DXd Q3W as neoadjuvant therapy prior to surgery; followed by 9 cycles of durvaluamb Q3W as adjuvant therapy post-surgery. Adjuvant chemotherapy may be given in combination with durvalumab only if participants have residual disease.

Olaparib may be given for participants with gBRCA-positive tumours and residual disease

Adjuvant chemotherapy may be one of these:

1. Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) and carboplatin (weekly or Q3W) for 4 cycles (12 weeks);
2. Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) for 4 cycles (12 weeks);
3. Carboplatin (weekly or Q3W) + paclitaxel (weekly) for 4 cycles (12 weeks);
4. Capecitabine (Q3W) for 8 cycles.

**Intervention Names:**

- Drug: Dato-DXd

- Drug: Durvalumab

- Drug: Doxorubicin

- Drug: Epirubicin

- Drug: Cyclophosphamide

- Drug: Paclitaxel

- Drug: Carboplatin

- Drug: Capecitabine

- Drug: Olaparib

**Label:** Dato-DXd plus durvalumab

**Type:** EXPERIMENTAL

#### Arm Group 2

**Description:** Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Adjuvant capecitabine (Q3W) for 8 cycles may be given in combination with pembrolizumab only if participants have residual disease. Olaparib may be given for participants with gBRCA-positive tumours and residual disease.

**Intervention Names:**

- Drug: Pembrolizumab

- Drug: Doxorubicin

- Drug: Epirubicin

- Drug: Cyclophosphamide

- Drug: Paclitaxel

- Drug: Carboplatin

- Drug: Capecitabine

- Drug: Olaparib

**Label:** Pembrolizumab plus chemotherapy

**Type:** ACTIVE_COMPARATOR

### Interventions

#### Intervention 1

**Arm Group Labels:**

- Dato-DXd plus durvalumab

**Description:** Experimental drug IV infusion

**Name:** Dato-DXd

**Other Names:**

- Datopotamab deruxtecan (Dato-DXd, DS-1062a)

**Type:** DRUG

#### Intervention 2

**Arm Group Labels:**

- Dato-DXd plus durvalumab

**Description:** Experimental drug IV Infusion

**Name:** Durvalumab

**Other Names:**

- MEDI4736

**Type:** DRUG

#### Intervention 3

**Arm Group Labels:**

- Pembrolizumab plus chemotherapy

**Description:** IV Infusion Active comparator

**Name:** Pembrolizumab

**Other Names:**

- KEYTRUDA®

**Type:** DRUG

#### Intervention 4

**Arm Group Labels:**

- Dato-DXd plus durvalumab

- Pembrolizumab plus chemotherapy

**Description:** IV infusion Experimental/Active Comparator

**Name:** Doxorubicin

**Type:** DRUG

#### Intervention 5

**Arm Group Labels:**

- Dato-DXd plus durvalumab

- Pembrolizumab plus chemotherapy

**Description:** IV Infusion Experimental/Active Comparator

**Name:** Epirubicin

**Type:** DRUG

#### Intervention 6

**Arm Group Labels:**

- Dato-DXd plus durvalumab

- Pembrolizumab plus chemotherapy

**Description:** IV infusion Experimental/Active Comparator

**Name:** Cyclophosphamide

**Type:** DRUG

#### Intervention 7

**Arm Group Labels:**

- Dato-DXd plus durvalumab

- Pembrolizumab plus chemotherapy

**Description:** IV infusion Experimental/Active Comparator

**Name:** Paclitaxel

**Type:** DRUG

#### Intervention 8

**Arm Group Labels:**

- Dato-DXd plus durvalumab

- Pembrolizumab plus chemotherapy

**Description:** IV infusion Experimental/Active Comparator

**Name:** Carboplatin

**Type:** DRUG

#### Intervention 9

**Arm Group Labels:**

- Dato-DXd plus durvalumab

- Pembrolizumab plus chemotherapy

**Description:** Tablet Oral route of administration Experimental/Active Comparator

**Name:** Capecitabine

**Other Names:**

- XELODA®, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord

**Type:** DRUG

#### Intervention 10

**Arm Group Labels:**

- Dato-DXd plus durvalumab

- Pembrolizumab plus chemotherapy

**Description:** Tablet Oral route of administration Experimental/Active Comparator

**Name:** Olaparib

**Other Names:**

- LYNPARZA®

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** pCR rate is defined as the proportion of participants who have no evidence by haematoxylin and eosin staining of residual invasive disease at the time of definitive surgery in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0) by blinded central evaluation.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest will be the difference between the pCR rates.

**Measure:** Pathologic Complete Response (pCR) in the experimental vs control arms

**Time Frame:** At the time of definitive surgery

**Description:** EFS is defined as the time from the date of randomisation until the date of the first occurrence of any of the following events: disease progression precluding surgery, disease recurrence (local, regional, distant, or contralateral), second primary non-breast invasive cancer (other than squamous or basal cell skin cancer), or death by any cause (in the absence of recurrence).

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest will be the Hazard Ratio of EFS.

**Measure:** Event-free survival (EFS) in the experimental vs control arms

**Time Frame:** Date of randomization to date of the EFS event, up to 68 months after the first subject randomized

#### Secondary Outcomes

**Description:** OS is defined as the time from the date of randomisation until the date of death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest will be the Hazard Ratio of OS.

**Measure:** Overall Survival (OS) in the experimental vs control arms

**Time Frame:** Date of randomization to date of death due to any cause, up to 82 months after the first subject randomized

**Description:** DDFS is defined as the time from the date of randomisation until the date of the first occurrence of any of the following events: distant metastasis, occurrence of second primary non-breast invasive cancer (other than squamous or basal cell skin cancer), or death by any cause (in the absence of recurrence).

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest will be the Hazard Ratio of DDFS.

**Measure:** Distant disease-free survival (DDFS) in the experimental vs control arms

**Time Frame:** Date of randomization to date of the DDFS event, up to 68 months after the first subject randomized

**Description:** Breast and arm symptoms measured by the EORTC IL116. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest is the mean between-arm difference in breast and arm symptom scores.

**Measure:** Participant-reported breast and arm symptoms in the experimental vs. control arms

**Time Frame:** From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first.

**Description:** Physical function measured by the PROMIS Physical Function Short Form 8c. The analysis will include all dosed participants. The measure of interest is the mean between-arm difference in physical function scores.

**Measure:** Participant-reported physical function in the experimental vs. control arms

**Time Frame:** From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).

**Description:** Fatigue measured by the PROMIS Fatigue Short Form 7a. The analysis will include all dosed participants. The measure of interest will be the difference on the proportions of participants reporting different levels of fatigue and mean between-arm difference in the fatigue scores.

**Measure:** Participant-reported fatigue in the experimental vs. control arms

**Time Frame:** From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).

**Description:** Global health status/Quality of life measured by EORTC IL172. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy.

The measure of interest is the mean between-arm difference in GHS/QoL scores.

**Measure:** Participant-reported Global health status/Quality of life (GHS/QoL)in the experimental vs. control arms

**Time Frame:** From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).

**Description:** Plasma concentrations of Dato-DXd (ug/ml )

**Measure:** Pharmacokinetics of Dato-DXd (in combination with durvalumab)

**Time Frame:** Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit

**Description:** Plasma concentrations of total anti-TROP2 antibody (ug/ml )

**Measure:** Pharmacokinetics of Dato-DXd (in combination with durvalumab)

**Time Frame:** Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit

**Description:** Plasma concentrations of DXd (MAAA-1181a) (ng/ml)

**Measure:** Pharmacokinetics of Dato-DXd (in combination with durvalumab)

**Time Frame:** Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit

**Description:** Presence of antidrug antibodies (ADAs) for Dato-DXd (confirmatory results: positive or negative, titres).

**Measure:** Immunogenicity of Dato-DXd (in combination with durvalumab)

**Time Frame:** Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit

**Description:** Safety and tolerability will be evaluated in terms of AEs graded by CTCAE version 5.0

**Measure:** Safety of Dato-DXd (in combination with durvalumab)

**Time Frame:** Randomization to final safety follow-up visit, either 90 days after last dose of study intervention for those who complete planned study intervention or 90 days after date of discontinuation for those who discontinue study intervention prematurely

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Participant must be ≥ 18 years, at the time of signing the ICF.
* Histologically confirmed Stage II or III unilateral or bilateral primary invasive TNBC or hormone receptor-low/HER2-negative breast cancer
* ECOG PS of 0 or 1
* Provision of acceptable tumor sample
* Adequate bone marrow reserve and organ function
* Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria:

* History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before randomization and of low potential risk for recurrence.
* Evidence of distant disease.
* Clinically significant corneal disease.
* Has active or uncontrolled hepatitis B or C virus infection.
* Known HIV infection that is not well controlled.
* Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections; or inability to rule out infections.
* Known to have active tuberculosis infection
* Resting ECG with clinically significant abnormal findings.
* Uncontrolled or significant cardiac disease.
* History of non-infectious ILD/pneumonitis
* Any prior or concurrent surgery, radiotherapy or systemic anticancer therapy for TNBC or hormone receptor-low/HER2-negative breast cancer
* For females only: is pregnant (confirmed with positive serum pregnancy test) or breastfeeding, or planning to become pregnant.
* Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of study intervention, or as dictated by local PI for SoC if longer.

**Minimum Age:** 18 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** information.center@astrazeneca.com

**Name:** AstraZeneca Clinical Study Information Center

**Phone:** 1-877-240-9479

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** Daphne

**Country:** United States

**Facility:** Research Site

**State:** Alabama

**Status:** NOT_YET_RECRUITING

**Zip:** 36526

**Location 2:**

**City:** Goodyear

**Country:** United States

**Facility:** Research Site

**State:** Arizona

**Status:** NOT_YET_RECRUITING

**Zip:** 85395

**Location 3:**

**City:** Phoenix

**Country:** United States

**Facility:** Research Site

**State:** Arizona

**Status:** NOT_YET_RECRUITING

**Zip:** 85054

**Location 4:**

**City:** Tucson

**Country:** United States

**Facility:** Research Site

**State:** Arizona

**Status:** NOT_YET_RECRUITING

**Zip:** 85711

**Location 5:**

**City:** Jonesboro

**Country:** United States

**Facility:** Research Site

**State:** Arkansas

**Status:** RECRUITING

**Zip:** 72401

**Location 6:**

**City:** Rogers

**Country:** United States

**Facility:** Research Site

**State:** Arkansas

**Status:** RECRUITING

**Zip:** 72758

**Location 7:**

**City:** Bakersfield

**Country:** United States

**Facility:** Research Site

**State:** California

**Status:** RECRUITING

**Zip:** 93309

**Location 8:**

**City:** Fullerton

**Country:** United States

**Facility:** Research Site

**State:** California

**Status:** RECRUITING

**Zip:** 92835

**Location 9:**

**City:** Los Angeles

**Country:** United States

**Facility:** Research Site

**State:** California

**Status:** NOT_YET_RECRUITING

**Zip:** 90033

**Location 10:**

**City:** Los Angeles

**Country:** United States

**Facility:** Research Site

**State:** California

**Status:** NOT_YET_RECRUITING

**Zip:** 90095

**Location 11:**

**City:** Orange

**Country:** United States

**Facility:** Research Site

**State:** California

**Status:** NOT_YET_RECRUITING

**Zip:** 92868

**Location 12:**

**City:** Santa Barbara

**Country:** United States

**Facility:** Research Site

**State:** California

**Status:** NOT_YET_RECRUITING

**Zip:** 93105

**Location 13:**

**City:** Santa Rosa

**Country:** United States

**Facility:** Research Site

**State:** California

**Status:** RECRUITING

**Zip:** 92805

**Location 14:**

**City:** Sylmar

**Country:** United States

**Facility:** Research Site

**State:** California

**Status:** WITHDRAWN

**Zip:** 91342

**Location 15:**

**City:** Torrance

**Country:** United States

**Facility:** Research Site

**State:** California

**Status:** RECRUITING

**Zip:** 90505

**Location 16:**

**City:** Van Nuys

**Country:** United States

**Facility:** Research Site

**State:** California

**Status:** NOT_YET_RECRUITING

**Zip:** 91405

**Location 17:**

**City:** Aurora

**Country:** United States

**Facility:** Research Site

**State:** Colorado

**Status:** NOT_YET_RECRUITING

**Zip:** 80045

**Location 18:**

**City:** Fort Collins

**Country:** United States

**Facility:** Research Site

**State:** Colorado

**Status:** NOT_YET_RECRUITING

**Zip:** 80528

**Location 19:**

**City:** Longmont

**Country:** United States

**Facility:** Research Site

**State:** Colorado

**Status:** NOT_YET_RECRUITING

**Zip:** 80504

**Location 20:**

**City:** Bridgeport

**Country:** United States

**Facility:** Research Site

**State:** Connecticut

**Status:** NOT_YET_RECRUITING

**Zip:** 06606

**Location 21:**

**City:** New Haven

**Country:** United States

**Facility:** Research Site

**State:** Connecticut

**Status:** RECRUITING

**Zip:** 06510

**Location 22:**

**City:** Newark

**Country:** United States

**Facility:** Research Site

**State:** Delaware

**Status:** WITHDRAWN

**Zip:** 19713

**Location 23:**

**City:** Fort Myers

**Country:** United States

**Facility:** Research Site

**State:** Florida

**Status:** NOT_YET_RECRUITING

**Zip:** 33901

**Location 24:**

**City:** Jacksonville

**Country:** United States

**Facility:** Research Site

**State:** Florida

**Status:** NOT_YET_RECRUITING

**Zip:** 32224

**Location 25:**

**City:** Jacksonville

**Country:** United States

**Facility:** Research Site

**State:** Florida

**Status:** RECRUITING

**Zip:** 32256

**Location 26:**

**City:** Port Saint Lucie

**Country:** United States

**Facility:** Research Site

**State:** Florida

**Status:** WITHDRAWN

**Zip:** 34952

**Location 27:**

**City:** Saint Petersburg

**Country:** United States

**Facility:** Research Site

**State:** Florida

**Status:** NOT_YET_RECRUITING

**Zip:** 33705

**Location 28:**

**City:** Tallahassee

**Country:** United States

**Facility:** Research Site

**State:** Florida

**Status:** NOT_YET_RECRUITING

**Zip:** 32308

**Location 29:**

**City:** West Palm Beach

**Country:** United States

**Facility:** Research Site

**State:** Florida

**Status:** NOT_YET_RECRUITING

**Zip:** 33401

**Location 30:**

**City:** Atlanta

**Country:** United States

**Facility:** Research Site

**State:** Georgia

**Status:** NOT_YET_RECRUITING

**Zip:** 30322

**Location 31:**

**City:** Atlanta

**Country:** United States

**Facility:** Research Site

**State:** Georgia

**Status:** NOT_YET_RECRUITING

**Zip:** 30342

**Location 32:**

**City:** Des Moines

**Country:** United States

**Facility:** Research Site

**State:** Iowa

**Status:** RECRUITING

**Zip:** 50309

**Location 33:**

**City:** Edgewood

**Country:** United States

**Facility:** Research Site

**State:** Kentucky

**Status:** NOT_YET_RECRUITING

**Zip:** 41017

**Location 34:**

**City:** Louisville

**Country:** United States

**Facility:** Research Site

**State:** Kentucky

**Status:** NOT_YET_RECRUITING

**Zip:** 40202

**Location 35:**

**City:** Baton Rouge

**Country:** United States

**Facility:** Research Site

**State:** Louisiana

**Status:** NOT_YET_RECRUITING

**Zip:** 70817

**Location 36:**

**City:** Annapolis

**Country:** United States

**Facility:** Research Site

**State:** Maryland

**Status:** NOT_YET_RECRUITING

**Zip:** 21401

**Location 37:**

**City:** Boston

**Country:** United States

**Facility:** Research Site

**State:** Massachusetts

**Status:** NOT_YET_RECRUITING

**Zip:** 02215

**Location 38:**

**City:** Detroit

**Country:** United States

**Facility:** Research Site

**State:** Michigan

**Status:** NOT_YET_RECRUITING

**Zip:** 48202

**Location 39:**

**City:** Grand Rapids

**Country:** United States

**Facility:** Research Site

**State:** Michigan

**Status:** RECRUITING

**Zip:** 49503

**Location 40:**

**City:** Traverse City

**Country:** United States

**Facility:** Research Site

**State:** Michigan

**Status:** RECRUITING

**Zip:** 49684

**Location 41:**

**City:** Burnsville

**Country:** United States

**Facility:** Research Site

**State:** Minnesota

**Status:** NOT_YET_RECRUITING

**Zip:** 55337

**Location 42:**

**City:** Minneapolis

**Country:** United States

**Facility:** Research Site

**State:** Minnesota

**Status:** NOT_YET_RECRUITING

**Zip:** 55407

**Location 43:**

**City:** Columbia

**Country:** United States

**Facility:** Research Site

**State:** Missouri

**Status:** NOT_YET_RECRUITING

**Zip:** 65212

**Location 44:**

**City:** Saint Louis

**Country:** United States

**Facility:** Research Site

**State:** Missouri

**Status:** WITHDRAWN

**Zip:** 63110

**Location 45:**

**City:** Omaha

**Country:** United States

**Facility:** Research Site

**State:** Nebraska

**Status:** NOT_YET_RECRUITING

**Zip:** 68130

**Location 46:**

**City:** Henderson

**Country:** United States

**Facility:** Research Site

**State:** Nevada

**Status:** NOT_YET_RECRUITING

**Zip:** 89074

**Location 47:**

**City:** Camden

**Country:** United States

**Facility:** Research Site

**State:** New Jersey

**Status:** NOT_YET_RECRUITING

**Zip:** 08103

**Location 48:**

**City:** East Brunswick

**Country:** United States

**Facility:** Research Site

**State:** New Jersey

**Status:** NOT_YET_RECRUITING

**Zip:** 08816

**Location 49:**

**City:** New Brunswick

**Country:** United States

**Facility:** Research Site

**State:** New Jersey

**Status:** NOT_YET_RECRUITING

**Zip:** 08901

**Location 50:**

**City:** Commack

**Country:** United States

**Facility:** Research Site

**State:** New York

**Status:** NOT_YET_RECRUITING

**Zip:** 11725

**Location 51:**

**City:** New York

**Country:** United States

**Facility:** Research Site

**State:** New York

**Status:** NOT_YET_RECRUITING

**Zip:** 10065

**Location 52:**

**City:** Port Jefferson Station

**Country:** United States

**Facility:** Research Site

**State:** New York

**Status:** WITHDRAWN

**Zip:** 11776

**Location 53:**

**City:** Charlotte

**Country:** United States

**Facility:** Research Site

**State:** North Carolina

**Status:** NOT_YET_RECRUITING

**Zip:** 28204

**Location 54:**

**City:** Durham

**Country:** United States

**Facility:** Research Site

**State:** North Carolina

**Status:** NOT_YET_RECRUITING

**Zip:** 27710

**Location 55:**

**City:** Canton

**Country:** United States

**Facility:** Research Site

**State:** Ohio

**Status:** RECRUITING

**Zip:** 44710

**Location 56:**

**City:** Eugene

**Country:** United States

**Facility:** Research Site

**State:** Oregon

**Status:** NOT_YET_RECRUITING

**Zip:** 97401

**Location 57:**

**City:** Portland

**Country:** United States

**Facility:** Research Site

**State:** Oregon

**Status:** NOT_YET_RECRUITING

**Zip:** 97223

**Location 58:**

**City:** Horsham

**Country:** United States

**Facility:** Research Site

**State:** Pennsylvania

**Status:** NOT_YET_RECRUITING

**Zip:** 19044

**Location 59:**

**City:** Philadelphia

**Country:** United States

**Facility:** Research Site

**State:** Pennsylvania

**Status:** NOT_YET_RECRUITING

**Zip:** 19104

**Location 60:**

**City:** Pittsburgh

**Country:** United States

**Facility:** Research Site

**State:** Pennsylvania

**Status:** NOT_YET_RECRUITING

**Zip:** 15212

**Location 61:**

**City:** Providence

**Country:** United States

**Facility:** Research Site

**State:** Rhode Island

**Status:** WITHDRAWN

**Zip:** 02903

**Location 62:**

**City:** Nashville

**Country:** United States

**Facility:** Research Site

**State:** Tennessee

**Status:** NOT_YET_RECRUITING

**Zip:** 37203

**Location 63:**

**City:** Austin

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 78731

**Location 64:**

**City:** Dallas

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Status:** WITHDRAWN

**Zip:** 75230

**Location 65:**

**City:** Dallas

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 75231

**Location 66:**

**City:** Dallas

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Status:** WITHDRAWN

**Zip:** 75246

**Location 67:**

**City:** Dallas

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 75390-8843

**Location 68:**

**City:** El Paso

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 79902

**Location 69:**

**City:** Flower Mound

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 75028

**Location 70:**

**City:** Fort Worth

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 76104

**Location 71:**

**City:** Houston

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 77030

**Location 72:**

**City:** San Antonio

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 78240

**Location 73:**

**City:** Webster

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Status:** NOT_YET_RECRUITING

**Zip:** 77598

**Location 74:**

**City:** Falls Church

**Country:** United States

**Facility:** Research Site

**State:** Virginia

**Status:** NOT_YET_RECRUITING

**Zip:** 22042

**Location 75:**

**City:** Norfolk

**Country:** United States

**Facility:** Research Site

**State:** Virginia

**Status:** NOT_YET_RECRUITING

**Zip:** 23502

**Location 76:**

**City:** Richmond

**Country:** United States

**Facility:** Research Site

**State:** Virginia

**Status:** WITHDRAWN

**Zip:** 23298

**Location 77:**

**City:** Roanoke

**Country:** United States

**Facility:** Research Site

**State:** Virginia

**Status:** NOT_YET_RECRUITING

**Zip:** 24014

**Location 78:**

**City:** Winchester

**Country:** United States

**Facility:** Research Site

**State:** Virginia

**Status:** NOT_YET_RECRUITING

**Zip:** 22601

**Location 79:**

**City:** Tacoma

**Country:** United States

**Facility:** Research Site

**State:** Washington

**Status:** RECRUITING

**Zip:** 98405

**Location 80:**

**City:** Madison

**Country:** United States

**Facility:** Research Site

**State:** Wisconsin

**Status:** WITHDRAWN

**Zip:** 53715

**Location 81:**

**City:** Darlinghurst

**Country:** Australia

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 2010

**Location 82:**

**City:** East Melbourne

**Country:** Australia

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 3002

**Location 83:**

**City:** Heidelberg

**Country:** Australia

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 3084

**Location 84:**

**City:** Herston

**Country:** Australia

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 4029

**Location 85:**

**City:** Nedlands

**Country:** Australia

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 6009

**Location 86:**

**City:** Waratah

**Country:** Australia

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 2298

**Location 87:**

**City:** Feldkirch

**Country:** Austria

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 6807

**Location 88:**

**City:** Graz

**Country:** Austria

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 8036

**Location 89:**

**City:** Innsbruck

**Country:** Austria

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 6020

**Location 90:**

**City:** Linz

**Country:** Austria

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 4010

**Location 91:**

**City:** Salzburg

**Country:** Austria

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 5020

**Location 92:**

**City:** Brasschaat

**Country:** Belgium

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 2930

**Location 93:**

**City:** Charleroi

**Country:** Belgium

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 6000

**Location 94:**

**City:** Gent

**Country:** Belgium

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 9000

**Location 95:**

**City:** Leuven

**Country:** Belgium

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 3000

**Location 96:**

**City:** Libramont-Chevigny

**Country:** Belgium

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 6800

**Location 97:**

**City:** Wilrijk

**Country:** Belgium

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 2610

**Location 98:**

**City:** Brasilia

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 71681-603

**Location 99:**

**City:** Curitiba

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 80440-220

**Location 100:**

**City:** Fortaleza

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 60336-045

**Location 101:**

**City:** Londrina

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 86015-520

**Location 102:**

**City:** Natal

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 59075-740

**Location 103:**

**City:** Porto Alegre

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 90035-000

**Location 104:**

**City:** Porto Alegre

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 90035-903

**Location 105:**

**City:** Ribeirão Preto

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 14051-140

**Location 106:**

**City:** Santo Andre

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 09060-650

**Location 107:**

**City:** São Paulo

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 01246-000

**Location 108:**

**City:** Taubaté

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 12030-200

**Location 109:**

**City:** Vitória

**Country:** Brazil

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 29043-260

**Location 110:**

**City:** Plovdiv

**Country:** Bulgaria

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 4004

**Location 111:**

**City:** Shumen

**Country:** Bulgaria

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 9700

**Location 112:**

**City:** Sofia

**Country:** Bulgaria

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 1330

**Location 113:**

**City:** Sofia

**Country:** Bulgaria

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 1431

**Location 114:**

**City:** Sofia

**Country:** Bulgaria

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 1797

**Location 115:**

**City:** Sofia

**Country:** Bulgaria

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Location 116:**

**City:** Vratza

**Country:** Bulgaria

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 3000

**Location 117:**

**City:** Calgary

**Country:** Canada

**Facility:** Research Site

**State:** Alberta

**Status:** NOT_YET_RECRUITING

**Zip:** T2N 4N2

**Location 118:**

**City:** Abbotsford

**Country:** Canada

**Facility:** Research Site

**State:** British Columbia

**Status:** NOT_YET_RECRUITING

**Zip:** V2S0C2

**Location 119:**

**City:** Vancouver

**Country:** Canada

**Facility:** Research Site

**State:** British Columbia

**Status:** NOT_YET_RECRUITING

**Zip:** VSZ 4E6

**Location 120:**

**City:** St. John's

**Country:** Canada

**Facility:** Research Site

**State:** Newfoundland and Labrador

**Status:** NOT_YET_RECRUITING

**Zip:** A1B 3V6

**Location 121:**

**City:** Barrie

**Country:** Canada

**Facility:** Research Site

**State:** Ontario

**Status:** NOT_YET_RECRUITING

**Zip:** L4M 6M2

**Location 122:**

**City:** London

**Country:** Canada

**Facility:** Research Site

**State:** Ontario

**Status:** NOT_YET_RECRUITING

**Zip:** N6A 5W9

**Location 123:**

**City:** Oshawa

**Country:** Canada

**Facility:** Research Site

**State:** Ontario

**Status:** RECRUITING

**Zip:** L1G 2B9

**Location 124:**

**City:** Toronto

**Country:** Canada

**Facility:** Research Site

**State:** Ontario

**Status:** NOT_YET_RECRUITING

**Zip:** M5G 2M9

**Location 125:**

**City:** Levis

**Country:** Canada

**Facility:** Research Site

**State:** Quebec

**Status:** RECRUITING

**Zip:** G6V 3Z1

**Location 126:**

**City:** Montreal

**Country:** Canada

**Facility:** Research Site

**State:** Quebec

**Status:** RECRUITING

**Zip:** H1T 2M4

**Location 127:**

**City:** Montreal

**Country:** Canada

**Facility:** Research Site

**State:** Quebec

**Status:** RECRUITING

**Zip:** H2X 0C1

**Location 128:**

**City:** Montreal

**Country:** Canada

**Facility:** Research Site

**State:** Quebec

**Status:** RECRUITING

**Zip:** H4A-3J1

**Location 129:**

**City:** Sherbrooke

**Country:** Canada

**Facility:** Research Site

**State:** Quebec

**Status:** RECRUITING

**Zip:** J1H 5N4

**Location 130:**

**City:** St-Jerome

**Country:** Canada

**Facility:** Research Site

**State:** Quebec

**Status:** RECRUITING

**Zip:** J7Z 5T3

**Location 131:**

**City:** Saskatoon

**Country:** Canada

**Facility:** Research Site

**State:** Saskatchewan

**Status:** NOT_YET_RECRUITING

**Zip:** S7N 4H4

**Location 132:**

**City:** Montreal

**Country:** Canada

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** H3T 1E2

**Location 133:**

**City:** Ottawa

**Country:** Canada

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** K1H 8L6

**Location 134:**

**City:** Beijing

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 100044

**Location 135:**

**City:** Beijing

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 211405

**Location 136:**

**City:** Bengbu

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 233060

**Location 137:**

**City:** Changchun

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 130021

**Location 138:**

**City:** Changsha

**Country:** China

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 410008

**Location 139:**

**City:** Changsha

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 410013

**Location 140:**

**City:** Chengdu

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 610000

**Location 141:**

**City:** Chongqing

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 400030

**Location 142:**

**City:** Guangzhou

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 510060

**Location 143:**

**City:** Guangzhou

**Country:** China

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 510120

**Location 144:**

**City:** Hangzhou

**Country:** China

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 310009

**Location 145:**

**City:** Hangzhou

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 310022

**Location 146:**

**City:** Harbin

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 150049

**Location 147:**

**City:** Hefei

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 230012

**Location 148:**

**City:** Jinan

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 250117

**Location 149:**

**City:** Kunming

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 650118

**Location 150:**

**City:** Linhai

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 318000

**Location 151:**

**City:** Nanchang

**Country:** China

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 330009

**Location 152:**

**City:** Nanchang

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 330029

**Location 153:**

**City:** Nanjing

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 210008

**Location 154:**

**City:** Nanjing

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 210029

**Location 155:**

**City:** Nanning

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 530021

**Location 156:**

**City:** Shanghai

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 200025

**Location 157:**

**City:** Shenyang

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 110004

**Location 158:**

**City:** Shenyang

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 110042

**Location 159:**

**City:** Shijiazhuang

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 050020

**Location 160:**

**City:** Suining

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 629000

**Location 161:**

**City:** Suzhou

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 215004

**Location 162:**

**City:** Tianjin

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 300060

**Location 163:**

**City:** Urumqi

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 830000

**Location 164:**

**City:** Wuhan

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 430022

**Location 165:**

**City:** Xi'an

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 710061

**Location 166:**

**City:** Xintai

**Country:** China

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 54031

**Location 167:**

**City:** Avignon

**Country:** France

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 84918

**Location 168:**

**City:** Bayonne

**Country:** France

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 64100

**Location 169:**

**City:** Caen Cedex 5

**Country:** France

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 41076

**Location 170:**

**City:** Clermont Ferrand

**Country:** France

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 63011

**Location 171:**

**City:** Limoges

**Country:** France

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 87000

**Location 172:**

**City:** Lyon

**Country:** France

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 69373

**Location 173:**

**City:** Marseille

**Country:** France

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 13273

**Location 174:**

**City:** Montpellier

**Country:** France

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 34298

**Location 175:**

**City:** Nice

**Country:** France

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 06100

**Location 176:**

**City:** Paris

**Country:** France

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 75010

**Location 177:**

**City:** Reims Cedex

**Country:** France

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 51056

**Location 178:**

**City:** Saint Herblain

**Country:** France

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 44805

**Location 179:**

**City:** Toulouse

**Country:** France

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 31100

**Location 180:**

**City:** Vandoeuvre les Nancy

**Country:** France

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 54519

**Location 181:**

**City:** Villejuif Cedex

**Country:** France

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 94805

**Location 182:**

**City:** Augsburg

**Country:** Germany

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 86150

**Location 183:**

**City:** Berlin

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 10967

**Location 184:**

**City:** Berlin

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 13125

**Location 185:**

**City:** Dessau-Roßlau

**Country:** Germany

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 06847

**Location 186:**

**City:** Dresden

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 01307

**Location 187:**

**City:** Erlangen

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 91054

**Location 188:**

**City:** Essen

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 45130

**Location 189:**

**City:** Esslingen am Neckar

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 73730

**Location 190:**

**City:** Frankfurt am Main

**Country:** Germany

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 60431

**Location 191:**

**City:** Freiburg

**Country:** Germany

**Facility:** Research Site

**Status:** SUSPENDED

**Zip:** 79106

**Location 192:**

**City:** Freiburg

**Country:** Germany

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 79110

**Location 193:**

**City:** Hannover

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 30559

**Location 194:**

**City:** Hannover

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 30625

**Location 195:**

**City:** Heidelberg

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 69120

**Location 196:**

**City:** Kiel

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 24105

**Location 197:**

**City:** Mainz

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 55131

**Location 198:**

**City:** Mannheim

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 68167

**Location 199:**

**City:** München

**Country:** Germany

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 80637

**Location 200:**

**City:** Münster

**Country:** Germany

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 48149

**Location 201:**

**City:** Trier

**Country:** Germany

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 54290

**Location 202:**

**City:** Ulm

**Country:** Germany

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 89075

**Location 203:**

**City:** Hong Kong

**Country:** Hong Kong

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 00000

**Location 204:**

**City:** Hong Kong

**Country:** Hong Kong

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 999077

**Location 205:**

**City:** Hong Kong

**Country:** Hong Kong

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Location 206:**

**City:** Kwai Chung

**Country:** Hong Kong

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 999077

**Location 207:**

**City:** Budapest

**Country:** Hungary

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 1122

**Location 208:**

**City:** Kecskemét

**Country:** Hungary

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 6000

**Location 209:**

**City:** Miskolc

**Country:** Hungary

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 3526

**Location 210:**

**City:** Nyíregyháza

**Country:** Hungary

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 4400

**Location 211:**

**City:** Salgótarján

**Country:** Hungary

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 3100

**Location 212:**

**City:** Szekszárd

**Country:** Hungary

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 7100

**Location 213:**

**City:** Bengaluru

**Country:** India

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 560085

**Location 214:**

**City:** Dehradun

**Country:** India

**Facility:** Research Site

**Status:** SUSPENDED

**Zip:** 248016

**Location 215:**

**City:** Delhi

**Country:** India

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 110029

**Location 216:**

**City:** Delhi

**Country:** India

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 110085

**Location 217:**

**City:** Kolkata

**Country:** India

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 700016

**Location 218:**

**City:** Kolkata

**Country:** India

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 700099

**Location 219:**

**City:** Marg Jaipur

**Country:** India

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 302004

**Location 220:**

**City:** Nagpur

**Country:** India

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 440001

**Location 221:**

**City:** Nashik

**Country:** India

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 422011

**Location 222:**

**City:** Puducherry

**Country:** India

**Facility:** Research Site

**Status:** SUSPENDED

**Zip:** 605006

**Location 223:**

**City:** Thiruvananthapuram

**Country:** India

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 695011

**Location 224:**

**City:** Vadodara

**Country:** India

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 391760

**Location 225:**

**City:** Empoli

**Country:** Italy

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 50053

**Location 226:**

**City:** Lucca

**Country:** Italy

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 55100

**Location 227:**

**City:** Macerata

**Country:** Italy

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 62100

**Location 228:**

**City:** Milano

**Country:** Italy

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 20132

**Location 229:**

**City:** Modena

**Country:** Italy

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 41124

**Location 230:**

**City:** Napoli

**Country:** Italy

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 80131

**Location 231:**

**City:** Padova

**Country:** Italy

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 35128

**Location 232:**

**City:** Roma

**Country:** Italy

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 00168

**Location 233:**

**City:** Rozzano

**Country:** Italy

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 20089

**Location 234:**

**City:** Torino

**Country:** Italy

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 10126

**Location 235:**

**City:** Tricase

**Country:** Italy

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 73039

**Location 236:**

**City:** Udine

**Country:** Italy

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 33100

**Location 237:**

**City:** Akashi-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 673-8558

**Location 238:**

**City:** Akita-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 010-8543

**Location 239:**

**City:** Bunkyo-ku

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 113-8431

**Location 240:**

**City:** Chiba-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 260-8717

**Location 241:**

**City:** Chuo-ku

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 104-8560

**Location 242:**

**City:** Fukuoka-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 811-1395

**Location 243:**

**City:** Fukushima-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 960-1295

**Location 244:**

**City:** Gifu-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 501-1194

**Location 245:**

**City:** Hidaka-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 350-1298

**Location 246:**

**City:** Hirakata-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 573-1191

**Location 247:**

**City:** Hiroshima-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 730-0011

**Location 248:**

**City:** Hiroshima-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 734-8551

**Location 249:**

**City:** Isehara-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 259-1193

**Location 250:**

**City:** Kashiwa

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 227-8577

**Location 251:**

**City:** Koto-ku

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 135-8550

**Location 252:**

**City:** Kumamoto-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 860-8556

**Location 253:**

**City:** Kurume-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 830-0011

**Location 254:**

**City:** Matsuyama-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 791-0280

**Location 255:**

**City:** Nagoya-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 460-0001

**Location 256:**

**City:** Nagoya-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 466-8560

**Location 257:**

**City:** Nagoya-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 467-0001

**Location 258:**

**City:** Niigata-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 951-8566

**Location 259:**

**City:** Okayama

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 700-8558

**Location 260:**

**City:** Osaka-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 541-8567

**Location 261:**

**City:** Sapporo-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 003-0804

**Location 262:**

**City:** Sapporo-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 060-8648

**Location 263:**

**City:** Sendai-shi

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 980-8574

**Location 264:**

**City:** Shinagawa-ku

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 142-8666

**Location 265:**

**City:** Shinjuku-ku

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 160-0023

**Location 266:**

**City:** Shinjuku-ku

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 162-8655

**Location 267:**

**City:** Sunto-gun

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 411-8777

**Location 268:**

**City:** Tokyo

**Country:** Japan

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 104-0045

**Location 269:**

**City:** Tsu-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 514-8507

**Location 270:**

**City:** Yokohama-shi

**Country:** Japan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 241-8515

**Location 271:**

**City:** Daegu

**Country:** Korea, Republic of

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 41404

**Location 272:**

**City:** Goyang-si

**Country:** Korea, Republic of

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 10408

**Location 273:**

**City:** Seongnam

**Country:** Korea, Republic of

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 13620

**Location 274:**

**City:** Seoul

**Country:** Korea, Republic of

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 02841

**Location 275:**

**City:** Seoul

**Country:** Korea, Republic of

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 03080

**Location 276:**

**City:** Seoul

**Country:** Korea, Republic of

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 03722

**Location 277:**

**City:** Seoul

**Country:** Korea, Republic of

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 05505

**Location 278:**

**City:** Seoul

**Country:** Korea, Republic of

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 06273

**Location 279:**

**City:** Seoul

**Country:** Korea, Republic of

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 06351

**Location 280:**

**City:** Seoul

**Country:** Korea, Republic of

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 06591

**Location 281:**

**City:** George Town

**Country:** Malaysia

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 10990

**Location 282:**

**City:** Kuala Lumpur

**Country:** Malaysia

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 50586

**Location 283:**

**City:** Kuala Lumpur

**Country:** Malaysia

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 59100

**Location 284:**

**City:** Kuching

**Country:** Malaysia

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 93586

**Location 285:**

**City:** Selangor

**Country:** Malaysia

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 62250

**Location 286:**

**City:** Bialystok

**Country:** Poland

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 15-027

**Location 287:**

**City:** Bydgoszcz

**Country:** Poland

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 85-796

**Location 288:**

**City:** Gdańsk

**Country:** Poland

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 80-214

**Location 289:**

**City:** Gdynia

**Country:** Poland

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 81-519

**Location 290:**

**City:** Tomaszów Mazowiecki

**Country:** Poland

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 97-200

**Location 291:**

**City:** Warszawa

**Country:** Poland

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 02-781

**Location 292:**

**City:** Wroclaw

**Country:** Poland

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 53-413

**Location 293:**

**City:** Łódź

**Country:** Poland

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 93-338

**Location 294:**

**City:** Singapore

**Country:** Singapore

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 168583

**Location 295:**

**City:** Barcelona

**Country:** Spain

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 08036

**Location 296:**

**City:** Barcelona

**Country:** Spain

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 8035

**Location 297:**

**City:** Granada

**Country:** Spain

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 18016

**Location 298:**

**City:** Hospitalet deLlobregat

**Country:** Spain

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 08907

**Location 299:**

**City:** Madrid

**Country:** Spain

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 28007

**Location 300:**

**City:** Madrid

**Country:** Spain

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 28034

**Location 301:**

**City:** Santiago de Compostela

**Country:** Spain

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 15706

**Location 302:**

**City:** Sevilla

**Country:** Spain

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 41009

**Location 303:**

**City:** Zaragoza

**Country:** Spain

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 50009

**Location 304:**

**City:** Baden

**Country:** Switzerland

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** CH-5405

**Location 305:**

**City:** Basel

**Country:** Switzerland

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 4031

**Location 306:**

**City:** Bern

**Country:** Switzerland

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 3010

**Location 307:**

**City:** Frauenfeld

**Country:** Switzerland

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 8501

**Location 308:**

**City:** Rennaz

**Country:** Switzerland

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 1847

**Location 309:**

**City:** Changhua

**Country:** Taiwan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 500

**Location 310:**

**City:** Kaohsiung

**Country:** Taiwan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 82445

**Location 311:**

**City:** Taichung

**Country:** Taiwan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 40447

**Location 312:**

**City:** Tainan

**Country:** Taiwan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 704

**Location 313:**

**City:** Taipei

**Country:** Taiwan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 10002

**Location 314:**

**City:** Taipei

**Country:** Taiwan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 10449

**Location 315:**

**City:** Taipei

**Country:** Taiwan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 112

**Location 316:**

**City:** Taoyuan

**Country:** Taiwan

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 333

**Location 317:**

**City:** Bangkok

**Country:** Thailand

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 10210

**Location 318:**

**City:** Bangkok

**Country:** Thailand

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 10330

**Location 319:**

**City:** Dusit

**Country:** Thailand

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 10300

**Location 320:**

**City:** Muang

**Country:** Thailand

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 50200

**Location 321:**

**City:** Songkhla

**Country:** Thailand

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 90110

**Location 322:**

**City:** Adapazari

**Country:** Turkey

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 54290

**Location 323:**

**City:** Ankara

**Country:** Turkey

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 06010

**Location 324:**

**City:** Ankara

**Country:** Turkey

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 06340

**Location 325:**

**City:** Ankara

**Country:** Turkey

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 06520

**Location 326:**

**City:** Istanbul

**Country:** Turkey

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 34722

**Location 327:**

**City:** Kayseri

**Country:** Turkey

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 38039

**Location 328:**

**City:** Samsun

**Country:** Turkey

**Facility:** Research Site

**Status:** RECRUITING

**Location 329:**

**City:** Birmingham

**Country:** United Kingdom

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** B15 2TG

**Location 330:**

**City:** Cardiff

**Country:** United Kingdom

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** CF14 2TL

**Location 331:**

**City:** Edinburgh

**Country:** United Kingdom

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** EH1 3EG

**Location 332:**

**City:** Guildford

**Country:** United Kingdom

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Location 333:**

**City:** Lancaster

**Country:** United Kingdom

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** LA1 4RP

**Location 334:**

**City:** London

**Country:** United Kingdom

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** EC1A 7BE

**Location 335:**

**City:** Northampton

**Country:** United Kingdom

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** NN1 5BD

**Location 336:**

**City:** Oxford

**Country:** United Kingdom

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** OX3 7LE

**Location 337:**

**City:** Hanoi

**Country:** Vietnam

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 100000

**Location 338:**

**City:** Hanoi

**Country:** Vietnam

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 100000

**Location 339:**

**City:** Ho Chi Minh city

**Country:** Vietnam

**Facility:** Research Site

**Status:** RECRUITING

**Zip:** 700000

**Location 340:**

**City:** Ho Chi Minh city

**Country:** Vietnam

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 700000

**Location 341:**

**City:** Vinh

**Country:** Vietnam

**Facility:** Research Site

**Status:** NOT_YET_RECRUITING

**Zip:** 460000

### IPD Sharing Statement Module

**Access Criteria:** When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

**Description:** Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

**Info Types:**

- STUDY_PROTOCOL

- SAP

**IPD Sharing:** YES

**Time Frame:** AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

**URL:** https://astrazenecagroup-dt.pharmacm.com/DT/Home

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000009371

- Term: Neoplasms by Site

- ID: D000009369

- Term: Neoplasms

- ID: D000001941

- Term: Breast Diseases

- ID: D000012871

- Term: Skin Diseases

### Condition Browse Module - Browse Branches

- Abbrev: BC04

- Name: Neoplasms

- Abbrev: BC17

- Name: Skin and Connective Tissue Diseases

- Abbrev: All

- Name: All Conditions

### Condition Browse Module - Browse Leaves

- ID: M5220

- Name: Breast Neoplasms

- Relevance: HIGH

- As Found: Breast Cancer

- ID: M5218

- Name: Breast Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M15674

- Name: Skin Diseases

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000001943

- Term: Breast Neoplasms

### Intervention Browse Module - Ancestors

- ID: D000000972

- Term: Antineoplastic Agents, Phytogenic

- ID: D000000970

- Term: Antineoplastic Agents

- ID: D000050257

- Term: Tubulin Modulators

- ID: D000050256

- Term: Antimitotic Agents

- ID: D000050258

- Term: Mitosis Modulators

- ID: D000045504

- Term: Molecular Mechanisms of Pharmacological Action

- ID: D000007166

- Term: Immunosuppressive Agents

- ID: D000007155

- Term: Immunologic Factors

- ID: D000045505

- Term: Physiological Effects of Drugs

- ID: D000018501

- Term: Antirheumatic Agents

- ID: D000018906

- Term: Antineoplastic Agents, Alkylating

- ID: D000000477

- Term: Alkylating Agents

- ID: D000019653

- Term: Myeloablative Agonists

- ID: D000074322

- Term: Antineoplastic Agents, Immunological

- ID: D000082082

- Term: Immune Checkpoint Inhibitors

- ID: D000000903

- Term: Antibiotics, Antineoplastic

- ID: D000059005

- Term: Topoisomerase II Inhibitors

- ID: D000059003

- Term: Topoisomerase Inhibitors

- ID: D000004791

- Term: Enzyme Inhibitors

- ID: D000000964

- Term: Antimetabolites, Antineoplastic

- ID: D000000963

- Term: Antimetabolites

- ID: D000067856

- Term: Poly(ADP-ribose) Polymerase Inhibitors

### Intervention Browse Module - Browse Branches

- Abbrev: All

- Name: All Drugs and Chemicals

- Abbrev: ANeo

- Name: Antineoplastic Agents

- Abbrev: ARhu

- Name: Antirheumatic Agents

- Abbrev: Infe

- Name: Anti-Infective Agents

### Intervention Browse Module - Browse Leaves

- ID: M9789

- Name: Hormones

- Relevance: LOW

- As Found: Unknown

- ID: M19537

- Name: Paclitaxel

- Relevance: HIGH

- As Found: Surgery

- ID: M231

- Name: Albumin-Bound Paclitaxel

- Relevance: LOW

- As Found: Unknown

- ID: M4225

- Name: Antibodies

- Relevance: LOW

- As Found: Unknown

- ID: M6727

- Name: Cyclophosphamide

- Relevance: HIGH

- As Found: Cycle

- ID: M7492

- Name: Doxorubicin

- Relevance: HIGH

- As Found: Women

- ID: M227339

- Name: Liposomal doxorubicin

- Relevance: LOW

- As Found: Unknown

- ID: M377

- Name: Capecitabine

- Relevance: HIGH

- As Found: Function

- ID: M349416

- Name: Pembrolizumab

- Relevance: HIGH

- As Found: Blind

- ID: M17954

- Name: Epirubicin

- Relevance: HIGH

- As Found: 12 hours

- ID: M18650

- Name: Carboplatin

- Relevance: HIGH

- As Found: System

- ID: M272500

- Name: Durvalumab

- Relevance: HIGH

- As Found: Non-Small Cell

- ID: M233003

- Name: Olaparib

- Relevance: HIGH

- As Found: Fentanyl

- ID: M2342

- Name: Immune Checkpoint Inhibitors

- Relevance: LOW

- As Found: Unknown

- ID: M10184

- Name: Immunoglobulins

- Relevance: LOW

- As Found: Unknown

- ID: M26197

- Name: Tubulin Modulators

- Relevance: LOW

- As Found: Unknown

- ID: M26196

- Name: Antimitotic Agents

- Relevance: LOW

- As Found: Unknown

- ID: M10212

- Name: Immunosuppressive Agents

- Relevance: LOW

- As Found: Unknown

- ID: M10201

- Name: Immunologic Factors

- Relevance: LOW

- As Found: Unknown

- ID: M20604

- Name: Antirheumatic Agents

- Relevance: LOW

- As Found: Unknown

- ID: M20942

- Name: Antineoplastic Agents, Alkylating

- Relevance: LOW

- As Found: Unknown

- ID: M3820

- Name: Alkylating Agents

- Relevance: LOW

- As Found: Unknown

- ID: M1346

- Name: Antineoplastic Agents, Immunological

- Relevance: LOW

- As Found: Unknown

- ID: M4222

- Name: Anti-Bacterial Agents

- Relevance: LOW

- As Found: Unknown

- ID: M4224

- Name: Antibiotics, Antitubercular

- Relevance: LOW

- As Found: Unknown

- ID: M7951

- Name: Enzyme Inhibitors

- Relevance: LOW

- As Found: Unknown

- ID: M4281

- Name: Antimetabolites

- Relevance: LOW

- As Found: Unknown

- ID: M205

- Name: Poly(ADP-ribose) Polymerase Inhibitors

- Relevance: LOW

- As Found: Unknown

### Intervention Browse Module - Meshes

- ID: D000017239

- Term: Paclitaxel

- ID: D000003520

- Term: Cyclophosphamide

- ID: D000016190

- Term: Carboplatin

- ID: C000582435

- Term: Pembrolizumab

- ID: D000004317

- Term: Doxorubicin

- ID: D000069287

- Term: Capecitabine

- ID: C000613593

- Term: Durvalumab

- ID: D000015251

- Term: Epirubicin

- ID: C000531550

- Term: Olaparib

### Misc Info Module

- Version Holder: 2024-05-24
